Davis JA - Search Results

1

ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?

Davis JA, Hashmi H. Davis JA, et al. Expert Opin Biol Ther. 2022 Apr;22(4):445-447. doi: 10.1080/14712598.2022.2035357. Epub 2022 Feb 2. Expert Opin Biol Ther. 2022. PMID: 35084284 No abstract available.

2

The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.

Davis JA, Shockley A, Hashmi H. Davis JA, et al. J Oncol Pharm Pract. 2022 Jun;28(4):960-968. doi: 10.1177/10781552211073517. Epub 2022 Jan 10. J Oncol Pharm Pract. 2022. PMID: 35006032 Review.

3

'Save the day with a Stem Cell Rescue': Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy.

Hashmi H, Shockley A, Davis JA. Hashmi H, et al. Among authors: davis ja. Bone Marrow Transplant. 2022 Mar;57(3):504-506. doi: 10.1038/s41409-022-01570-4. Epub 2022 Jan 17. Bone Marrow Transplant. 2022. PMID: 35039623 No abstract available.

4

Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature.

Masood A, Wahab A, Iqbal Q, Davis J, Ehsan H, Hashmi H. Masood A, et al. Bone Marrow Transplant. 2022 Jun;57(6):866-873. doi: 10.1038/s41409-022-01668-9. Epub 2022 Apr 11. Bone Marrow Transplant. 2022. PMID: 35411107 Review.

5

'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.

Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. Davis JA, et al. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e680-e684. doi: 10.1016/j.clml.2022.03.006. Epub 2022 Mar 22. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35414476

6

Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.

Davis J, McGann M, Shockley A, Hashmi H. Davis J, et al. Expert Rev Hematol. 2022 Jun;15(6):473-475. doi: 10.1080/17474086.2022.2081147. Epub 2022 May 26. Expert Rev Hematol. 2022. PMID: 35603733 No abstract available.

7

Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy.

McGann M, Davis JA, Gaffney KJ, Smith D, Edwards K, Hess BT, Hashmi H. McGann M, et al. Among authors: davis ja. Transplant Cell Ther. 2022 Sep;28(9):583-585. doi: 10.1016/j.jtct.2022.06.021. Epub 2022 Jun 30. Transplant Cell Ther. 2022. PMID: 35781100 Free article. No abstract available.

8

Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant.

Shockley A, Davis JA, Gaffney KJ, Smith D, Weeda E, Hashmi H. Shockley A, et al. Among authors: davis ja. J Oncol Pharm Pract. 2022 Oct;28(7):1613-1616. doi: 10.1177/10781552221112320. Epub 2022 Jul 5. J Oncol Pharm Pract. 2022. PMID: 35790453

9

Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.

Masood A, Iqbal Q, Ehsan H, Davis JA, Hansen DK, Hashmi H. Masood A, et al. Among authors: davis ja. Ann Hematol. 2022 Dec;101(12):2601-2610. doi: 10.1007/s00277-022-04999-1. Epub 2022 Oct 10. Ann Hematol. 2022. PMID: 36214853 Review.

10

Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.

Davis JA, Gaffney KJ, McGann M, Smith D, Edwards K, Baldino E, Bakos K, Butcher C, Greenwell B, Hess BT, Hashmi H. Davis JA, et al. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e14-e18. doi: 10.1016/j.clml.2022.09.005. Epub 2022 Oct 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36319568 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,058 results

Search Page

Filters